Investors Lead Class Action Against Pacira BioSciences for Securities Fraud Allegations

Overview of the Lawsuit

In January 2025, the Rosen Law Firm announced they would be representing a shareholder who has initiated a class action lawsuit against Pacira BioSciences, Inc. This lawsuit pertains to the purchase of the company's securities made between August 2, 2023 and August 8, 2024. The firm is seeking investors who may have been impacted by alleged misleading statements regarding Pacira's patent protections for Exparel, an essential part of the company's revenue model.

Key Details of the Case

The lawsuit alleges that during the specified time frame, Pacira's executives misled investors by indicating that they had sufficient patent protections for Exparel. According to the plaintiffs, this false representation fostered a belief that the company could successfully expand its marketing, production, and sales strategies, which were vital for their ongoing growth. The suit asserts that the executives were aware that the patent protections were not as robust as they claimed and continued to publicly assert their strength.

Specifically, the lawsuit points to a significant ruling from the New Jersey District Court on June 6, 2023, which favored eVenus in a related case, suggesting that Pacira's claims were more fragile than publicly declared. The firm claims that Pacira's false optimism regarding its patent protections shattered investor confidence once the truth was laid bare, resulting in financial losses.

How to Get Involved

Investors who bought Pacira shares during the designated Class Period are urged to consider their legal options. Those wishing to act as lead plaintiffs must file a motion with the court by March 14, 2025. It's crucial for potential class members that they are aware that no class has yet been certified, meaning they are not represented unless they choose to retain individual counsel.

Interested parties can join the class action lawsuit through the Rosen Law Firm's online form or by directly contacting Phillip Kim, Esq. The law firm emphasizes the importance of experienced legal representation in securities class actions, directing investors to choose counsel with a proven track record in handling complex cases successfully.

About Rosen Law Firm

Rosen Law Firm is well-recognized in the realm of investor rights. The firm has been involved in numerous high-profile securities class actions, achieving record settlements for its clients. For instance, in 2017, it was ranked number one for the number of securities class action settlements, and in 2019, recovered over $438 million for affected investors. Partner Laurence Rosen has been acknowledged as a leader in the plaintiffs’ bar, reinforcing the firm's robust credentials in this field.

Additional Information

For any investor seeking to gather further information on joining the class action or understanding their rights in the context of this lawsuit, they can follow Rosen Law Firm on platforms like LinkedIn, Twitter, and Facebook for real-time updates. Furthermore, the law firm encourages all potential participants to review their options and consult with professionals to navigate the complexities of securities law effectively.

For a complete overview, contact details are available through the firm's main office in New York.

Note: This article will be continuously updated as the situation develops, providing investors with the latest legal insights and potential pathways for engagement and recovery.